Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs
By Josh Beckerman
Cabaletta Bio shares were down 32% to $12.72 after the U.S. Food and Drug Administration said it is looking into reports of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Cantor Fitzgerald analyst Josh Schimmer also mentioned Gracell Biotechnologies and Autolus Therapeutics as stocks that were "obviously" down in connection with the FDA's announcement. Gracell was recently down 17% to $4.46 while Autolus declined 11% to $4.50. Schimmer said the FDA investigation is "Likely a Storm in A Tea Cup."
The FDA lists several approved products in the category, such as Yescarta from Gilead Sciences. It said "the overall benefits of these products continue to outweigh their potential risks for their approved uses."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 28, 2023 14:44 ET (19:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks